There is an enormous unmet medical need to treat patients with uncurable, chronic conditions - especially Inflammatory Bowel Disease (IBD), such as Crohn’s & ulcerative colitis.
Enter Trellus Health (TRLS ). An early pioneer in this space, providing a ‘1st-of-its-kind’ IBD resilience/AI enabled chronic disease management platform. Which not only enables adults (17+) to take greater control of their own long term care.
But also shifts more towards preventative healthcare & telemedicine - thus freeing up vital resource within over-burdened systems (NHS).
Today TRLS said that it had launched a new lower-priced (vs B2B) Direct-to Consumer (DTC) service in the New York, New Jersey & Connecticut areas - with plans to expand later in 2022 across another 17 states.
This strategy makes perfect sense to me, since it further stress tests the platform, increases patient volumes and generates greater, real world clinical data/evidence.
Wrt the numbers, no specific guidance was given – albeit house broker Singer Capital Markets have reiterated their sales forecasts of $3.1m (-$9.2m EBITDA) and $18.2m (-$3.7m) respectively for this year & next. Alongside calculating a ‘conservative’ Target Price of 47.5p/share.
Going forward, 2023 will be a pivotal year in terms of B2B commercial adoption by large multi-year payers (eg health organisations, corporates, etc) – with the added attraction of rolling out the service internationally and across other therapeutic applications in due course.